Physician profile
Sara King
NPI 1841603305
$1,677.94
in general payments reported to CMS, 2019-2025
15 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $263 · 2023: $337 · 2024: $442 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $390.74 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $264.63 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $182.94 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.72 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $174.86 | 2021-2022 | |
| Abbvie INC. | $127.79 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.51 | 2025 | Cobenfy |
| Tris Pharma INC | $56.36 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $51.10 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $46.37 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $44.54 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $37.59 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $34.69 | 2024 | Qelbree |
| Neurocrine Biosciences, INC. | $19.22 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.88 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.